Sbir phase i: novel hyaluronan enhanced polymeric trans-catheter aortic valve
Ended Project Grant Awarded Last action
- Award ID
- R43HL158387
- Recipient
-
Youngheartvalve, Inc. UEI KDSXAGSGZGV1
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,327,257
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Originally
- Funding
-
- $884,838.00 Federal
- $442,419.00 Non-federal
- Place of performance
- Atlanta, GA 30313, USA
Award details come from USAspending.gov.
Description
- Abstract
- Our long-term goal is to commercialize hyaluronan enhanced polymeric transcatheter aortic valves (haptavs) that have the durability of surgically implanted mechanical valves, do not require life-long anticoagulation, avoid the emerging problems for tissue-based tavs, and are made from low-cost, synthetic materials using automated manufacturing. A novel biomaterial, made of engineering plastic (polyethylene) that, at a molecular level, is interlocked with a naturally occurring biomolecule (hyaluronan or HA) is used to make highly hydrophilic, blood-friendly polymer leaflets with the durability of engineered synthetic polymers. In both the laboratory and in live sheep, these valves have shown excellent hemodynamic performance and durability without any thrombus formation or calcification. With this phase i application we aim to demonstrate that the long-term durability, hemodynamics, and performance of the haptavs meet or exceed international standards, and take the initial steps toward developing a commercialization strategy to position the business for phase II sbir and series a funding. We will use our current phase i design prototype haptavs in both aims 1 and 2. Aim 1 will have independent entities test the long-term fatigue and hemodynamic performance according to international (ISO) standards. Aim 2 will work with a standard industry contract research organization (namsa) to prepare an FDA pre-submission and regulatory strategy, and facilitate a meeting with the FDA. We will work with larta INC. To develop our commercialization strategy for a phase II submission. Youngheartvalve, LLC was CO-founded in early 2020 by DR. Dasi (chief technology officer), an expert in heart valve engineering and cardiovascular biomechanics, and DR. James (chief operating officer), who is an established polymer materials scientist, and the inventor of HA-polyethylene materials. MR. Todd tomba, joined youngheartvalve mid 2020 as CEO and president. He brings over three decades of medical device industry, and specifically heart valve replacement commercialization experience, to the team.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $442,419 | $0 | |
| Original award | $442,419 | $442,419 |
Quick answers
Who received award R43HL158387?
R43HL158387 was awarded to Youngheartvalve, Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on August 1, 2021.
How much is award R43HL158387 worth?
$1,327,257 has been obligated on R43HL158387: $884,838 in federal funding and $442,419 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award